Orexo’s partner, Gesynta Pharma, announces positive phase I results for OX-MPI.
UPPSALA, Sweden, May 15, 2020 /PRNewswire/ -- Orexo‘s partner, Gesynta Pharma, today announces positive phase I results for OX-MPI (GS-248). Gesynta Pharma, who owns all the rights to OX-MPI (GS-248), aims to develop a treatment for the microvascular diseases in chronic inflammatory conditions. The purpose of the first clinical study was to evaluate safety, tolerability, pharmacokinetic and pharmacodynamic properties of OX-MPI (GS-248) after single and multiple ascending doses to healthy subjects.
The results support further clinical development of OX-MPI (GS-248) and a clinical phase II study is being planned.
The study will be presented at the 2020 EULAR e-congress June 3-6.
For more information read Gesynta Pharma’s press release attached below.
CONTACT:
Orexo
Box 303 751 05 Uppsala
+46 (0)18 780 88 00
+46 (0)18 780 88 88
http://www.orexo.com
info@orexo.se
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| Orexo´s partner Gesynta Pharma announces positive results from phase 1 study for OX-MPI |
View original content:http://www.prnewswire.com/news-releases/orexos-partner-gesynta-pharma-announces-positive-results-from-phase-1-study-for-ox-mpi-301060007.html
SOURCE Orexo
Company Codes: Stockholm:ORX, OTC-PINK:ORXOY, ISIN:SE0000736415, RICS:ORX.ST, Frankfurt:C5G, LSE:0H19, OTC-PINK:ORXOF
